MedTrace Logo

Exceptional Responders With Solid Tumor Cancer to Chemotherapy

NCT02555735 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2023-02-01

No results posted yet for this study

Summary

This is an observational study enrolling patients with Solid Tumor cancers to identify genomic expression differences between exceptional responders and non-responders to standard of care chemotherapy. Data analysis of the gene expression profile of the exceptional responders compared to non-responders will define genomic patterns that may help understand their response to chemotherapy.

Conditions

  • Solid Tumor Neoplasms

Interventions

DRUG

Standard of Care Chemotherapy

Physician's Choice Chemotherapy Treatment (non-guided)

Sponsors & Collaborators

  • The Pancreatic Cancer Treatment Center of Los Angeles

    collaborator UNKNOWN

  • Adera Labs, LLC

    lead INDUSTRY

Principal Investigators

  • Brian McCarthy, PhD · Adera Labs

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2026-12-31
Completion
2027-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02555735 on ClinicalTrials.gov